Navigation Links
Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Date:12/10/2010

icant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

(i)  Cleeland CS, et al. Pain and its treatment in outpatients with metastatic cancer.N Eng J Med. 1994: 330:592-596.

(ii)  Janjan N.Bone metastases: Approaches to management. Semin Oncol. 2001: 28:28-34.

(iii)  Schulman KL, Kohles J. Economic burden
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Amgen to Present at Deutsche Banks 2010 BioFEST
2. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
3. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
4. Choices
5. Empowerment Competition
6. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
7. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
8. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
9. Amgen Announces Webcast of 2010 Third Quarter Financial Results
10. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
11. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 2014  Paper Pak Industries, a manufacturer of ... Body Guard Bio, a disposable, highly absorbent ... and virus while protecting service providers and the ... a rugged, external nylon shell, watertight zipper, thermal ... inner chamber that contains contaminated and potentially contagious ...
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
... Md., Feb. 23, 2011 The Cystic Fibrosis Foundation and ... development that targets the defective protein that causes cystic fibrosis, ... The trial was designed to evaluate patients age ... a CF mutation called G551D. The study included 161 patients ...
Cached Medicine Technology:Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... -- Interrupting blood supply to an arm or a leg ... the surgery, according to a new study. "During ... the heart to be able to operate on it. After ... ability to produce energy because it doesn,t get oxygen. When ... such as an arm or a leg, the body prepares ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... 23, 2014 (HealthDay News) -- A large influx of ... is to avoid tens of thousands of deaths from ... researchers predict. Using a specially designed mathematical ... the outbreak in just one densely populated county of ... city of Monrovia. The researchers said that if ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... Despite initiatives, level of diversity among faculty, practitioners still ... say , ANN ARBOR, Mich. , Jan. ... medical school faculty remains low, even as the U.S. population ... currently being trained in medicine is unlikely to reverse those ...
... , Jan. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... in 2010. Each of the dividends will be $0.50 per share. ... to all stockholders who own shares of PDL on March 15, 2010 ... October 1, 2010 to all stockholders who own shares of PDL on ...
... , ... of Hematology (ASH) now offers physicians who diagnose and treat ... (CME) credits while staying abreast of the latest clinical strategies ... with Medscape, an online network of medical content for physicians ...
... , BRIGHTON, Mich. , ... alcohol and drug treatment provider in North America, has signed a ... a Saudi Arabian company to build a 291,000 square-foot, 250 ... the entire Islamic Mideast. , Brighton Hospital, the Addiction Treatment ...
... for ovarian cancer does not appear to detect early-stage ovarian ... 1 out of 100 women in the general population with ... in the Journal of the National Cancer Institute . ... in Seattle assessed the predictive value of certain symptoms, including ...
... vaccine developed using non-infectious virus-like particles (VLP) has ... mosquito-borne pathogen that has infected millions of people ... researchers at the National Institutes of Health have ... Allergy and Infectious Diseases (NIAID) developed the vaccine ...
Cached Medicine News:Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 2Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 3Health News:PDL BioPharma Announces Two $0.50 Dividends in 2010 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 2Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 4Health News:Symptoms have little value for early detection of ovarian cancer 2Health News:Virus-like particle vaccine protects monkeys from chikungunya virus 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: